A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney D… (NCT07571746) | Clinical Trial Compass
RecruitingPhase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
United States43 participantsStarted 2026-03-28
Plain-language summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant must be 18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age inclusive, at the time of signing the informed consent.
✓. Diagnosis of anti-PLA2R antibody-positive pMN.
✓. All participants must have received SoC therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for ≥ 4 weeks, with exceptions in case of intolerance, contraindications, or low blood pressure, before the screening period.
✓. Positive for anti-PLA2R.
✓. Up to date with required vaccinations as per institutional guidelines (eg, influenza, pneumococcal, and severe acute respiratory syndrome coronavirus 2) prior to study entry.
✓. Male and/or female assigned at birth, inclusive of all gender identities. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
✓. Capable of giving signed informed consent
Exclusion criteria
✕. Receipt of B cell-depleting therapy including CD19- or CD20-directed monoclonal antibodies \< 9 months before screening.
✕. Immunomodulatory therapy \<3 months before screening.
✕. Secondary causes of membranous nephropathy
✕. Diabetes mellitus with haemoglobin A1C \> 8.5% tested at screening visit.
What they're measuring
1
Number of participants with adverse events.
Timeframe: Through study completion, an average of 2 years
2
Change from baseline in UPCR (from 24-hour urine collection or the intended 24-hour urine collection)